Background {#Sec1}
==========

Pancreatic cancer is fatal for most patients, and it is the fourth leading cause of death from malignancies in Japan. Only surgical resection offers a potentially curative approach, but merely 5 to 25% of patients present with resectable disease \[[@CR1], [@CR2]\]. Approximately 35% of patients with pancreatic cancer have unresectable locally advanced pancreatic cancer (LAPC), and the treatment for them is chemotherapy with or without radiotherapy \[[@CR3]\]. The prognosis of LAPC patients has been poor, with a median survival of 9 to 13 months and 5-year overall survival (OS) of \< 5%. Distant metastases are a dominant cause of disease progression. However, a recent autopsy study revealed that about one-third of patients with pancreatic cancer die from locally destructive disease rather than distant metastasis \[[@CR4]\]. This suggests that local control is meaningful to prevent tumor progression and improved survival of LAPC patients.

For several decades, the role of radiotherapy for LAPC remained controversial. Since the 1980s, several randomized control trials of LAPC patients comparing chemoradiotherapy (CRT) with chemotherapy were conducted \[[@CR5]--[@CR7]\]. However, the results were contradictory. The results of a recently published randomized LAP07 trial demonstrated no significant survival benefits with the addition of radiotherapy to chemotherapy for LAPC patients \[[@CR8]\]. In addition, more intensive regimens of chemotherapy, such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, are reported to improve survival of metastatic pancreatic cancer patients, and are expected to be effective for LAPC patients \[[@CR9]--[@CR11]\]. This raises serious questions about the role of radiotherapy in the management of LAPC patients.

The biggest problem with CRT for pancreatic cancer is that tumor is surrounded by radiosensitive gastrointestinal (GI) organs, such as the stomach and the duodenum. This anatomical situation makes it difficult to deliver high doses to tumor without increasing irradiation dose to GI organs. The severe GI toxicity is related with the irradiated volume and dose received on the stomach and duodenum \[[@CR12]\]. With the introduction of intensity-modulated radiotherapy (IMRT) which can simultaneously reduce the dose to surrounding normal organs, while allowing an increase in target tumor dose, it is expected that the rate of GI toxicities will be reduced and the efficacy may be increased \[[@CR13], [@CR14]\].

In our institution, we have been performing IMRT for LAPC since 2009. Before IMRT, we treated LAPC patients with 3DCRT at a total dose of 54 Gy/30 fr. with weekly gemcitabine at 250 mg/m^2^ based on the results of phase I and phase II trials in our institution \[[@CR15], [@CR16]\]. The treatment regimen was well-tolerated and provided prolonged survival in LAPC patients; the 1-year survival rate was 74% and the MST was 16.6 months. However, the rate of distant metastasis was high. When we introduced IMRT for LAPC, we decided to use full dose gemcitabine in combination with radiotherapy and shorten radiation fractionation from thirty to fifteen, based on a previous report \[[@CR17]\]. We conducted phase I dose escalation study to determine the maximum tolerated radiation dose delivered by IMRT with full-dose gemcitabine, and it was 48 Gy/15 fr., (biological equivalent dose (BED~10~) = 63.4Gy, UMIN000004589). In this study, our aim is to retrospectively evaluate the effect of IMRT on outcomes and treatment-related acute and late GI toxicities compared with 3DCRT for LAPC.

Methods {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

The clinical data of LAPC patients treated with definitive CRT from September 2001 to March 2015 at our institution were retrospectively reviewed. Locally advanced unresectable disease was defined as superior mesenteric artery or celiac axis encasement \> 180 degrees, unreconstructible superior mesenteric vein/portal occlusion, or aortic invasion. Patient, tumor, and treatment characteristics were obtained from the medical records.

All patients were monitored weekly during CRT for acute GI toxicities, including nausea, vomiting, diarrhea, and abdominal pain. After CRT ended, patients were followed up once every 2 months, and monitored for late GI toxicities, including gastroduodenal ulcer and hemorrhage. All toxicities were scored according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. The institutional Review Board of Kyoto University Hospital approved this study.

Chemotherapy {#Sec4}
------------

The regimen of induction chemotherapy consisted of weekly intravenous administration of 1000 mg/m^2^ of gemcitabine on days 1, 8, 15 during 4-weeks. The regimens of CRT consisted of weekly gemcitabine 250 mg/m^2^ (for 3DCRT) or 1000 mg/m^2^ (for IMRT). As additional treatment after radiotherapy, 3 weekly doses of gemcitabine at 1000 mg/m^2^ every 28 days were administered until the tumor progression or patient refusal. If patients had some complications associated with gemcitabine, such as intestinal pneumonia, 80 mg/m^2^/day of S-1 was administered orally during radiotherapy twice daily on weekdays. After first-line gemcitabine-based therapy, S-1 based chemotherapies are the most frequently used, although this was left to the discretion of the medical oncologist.

Radiotherapy {#Sec5}
------------

Treatment-planning computed tomography (CT) was performed with intravenous contrast media, without oral contrast agents. The gross target volume (GTV) included radiographically apparent gross tumor and suspicious/enlarged lymph nodes on CT simulation for 3DCRT plans. The clinical target volume (CTV) was defined as the GTV plus a 5-mm margin in all directions. The CTV also included the potential para-aortic lymph node and neuroplexus involvement between the celiac axis and the superior mesenteric artery. The planned target volume (PTV) was determined by adding a horizontal 5-mm margin and a cephalocaudal 10-mm margin to the CTV, considering respiratory movement. A total dose of 54 Gy was delivered in 30 fractions, using 3- or 4-field planning and a dynamic arc conformal technique.

For IMRT plans, the GTV and CTV were the same as those of 3DCRT plans. The PTV was generated by adding a 5-mm margin in all directions to the CTV in consideration of respiratory management. For IMRT, breath-hold method or tumor dynamic tracking method were adopted for the management of tumor respiratory motion. IMRT planning was performed, using a commercially available planning system (Eclipse™ Varian, Medical Systems, Palo Alto, CA). The prescription dose was specified as D95 (the dose that covers 95% of the structure) to PTV-boost, a volume that subtracted normal organs (the stomach and the duodenum) plus 5- to 10-mm margins from PTV. The prescription dose was individualized between 39 and 51 Gy/15 fr. by achieving the dose constrain for OARs and referring to a previous institutional trial (UMIN000004589). The dose constraints of the OARs are listed in Table [1](#Tab1){ref-type="table"}. The standard beam arrangement involved five to six gantry angles. Treatment was delivered using dynamic multileaf collimation.Table 1Dose constraints for OARStructureConstraintsStomach/DuodenumV45 Gy \< 1 ccV42 Gy \< 5 ccV39 Gy \< 25 ccStomach + PRV/Duodenum + PRVV39 Gy \< 30 ccV36 Gy \< 45 ccSpinal cordDmax \< 36 GySpinal cord + PRVD2 cc \< 39 GyKidney (at least one)V20 Gy \< 30%LiverDmean \< 30 Gy*Abbreviations*; *OAR* organs at risk, *PRV* planning organ at risk volume, *Dmax* he maximum dose to the structure volume, *Dmean* the mean dose to the structure volume, *D2 cc* the maximum dose covering ≥2 cc of the structure volume, *VxxGy* the volume of the structure receiving \> xx Gy

Statistics {#Sec6}
----------

Fisher exact test was performed to compare the characteristics of patients treated with 3DCRT versus those treated with IMRT. Overall survival (OS) was defined as the period from the chemotherapy or chemoradiotherapy starting date to the date of death of any cause, and it was censored at the last follow-up visit for living patients. The Kaplan-Meier method was used to estimate the OS, LRPFS, and DMFS. The log-rank test was performed for the OS, LRPFS, and DMFS comparisons. The Cox proportional hazard model was used to estimate the hazard ratio. The chi-squared test was used to compare the rates of acute GI toxicities and the Gray's test was used to compare the cumulative incidence rates of late GI toxicities of patients treated with 3DCRT versus those with IMRT. All statistical tests were 2-sided. The difference was deemed statistically significant when the *p* value was \<.05. All statistical analyses were performed using EZR version 1.11 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R version 2.13.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec7}
=======

Patient and tumor characteristics {#Sec8}
---------------------------------

In total, 107 consecutive patients who underwent CRT for LAPC from September 2001 to March 2015 were included in this analysis; 80 patients were treated with 3DCRT (75%), and 27 patients with IMRT (25%). Of the 107 patients, 58% were male, and the median age at diagnosis was 65 years old (range, 35--85 years old). Fifty-three percent of tumors were located in the head/neck of the pancreas and 47% in the body/tail.

Sixty-three (59%) patients received induction chemotherapy, administered for 1--12 months prior to radiotherapy. In our protocol of IMRT clinical trial, the induction chemotherapy is one course of weekly administration of gemcitabine on days 1, 8, 15 during 4-weeks. All patients received concurrent chemotherapy during radiotherapy. Most patients (93%) received gemcitabine, 8 patients (7%) received it with S-1. Median radiation doses and fractions for 3DCRT and IMRT were 54 Gy/30 fr. (range, 48.6--55.6 Gy) and 48 Gy/15 fr. (range, 39--51 Gy), respectively. Patient, tumor, and treatment characteristics are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Patient characteristics of tumors and treatmentCharacteristic3DCRTIMRT*p*-valueNumber of patients (n)8027Age (median, range)65, 35--8566, 42--840.57Gender (male/female)45/3510/170.65PS (0--1/2)74/627/00.33Tumor location(head, uncus/body, tail)41/3916/100.51Tumor size (median, range \[mm\])29, 19--4030, 10--700.038Induction chemotherapy (yes/no)36/4427/0\< 0.01Concurrent chemotherapy (Gemcitabine/S-1)73/726/10.68Radiation dose (median, range \[Gy\])54, 48.6--55.848, 39--51Radiation fractionation (median, range)30, 27--3115, 15--15*Abbreviations*; *PS* performance status

Treatment outcome {#Sec9}
-----------------

Median follow-up period was 16.4 months, which was similar between groups. The 1-year OS rate of all patients was 74.3%, and median survival time (MST) was 17.5 months. The 1-year OS rates in the 3DCRT and IMRT groups were 68.2 and 92.3%, respectively (*p* = 0.0369). The 1-year LRPFS rates in the 3DCRT and IMRT groups were 63.2 and 73.1%, respectively (*p* = 0.0349). The 1-year DMFS rates in the 3DCRT and IMRT groups were 48.4 and 49.3%, respectively (*p* = 0.308) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Kaplan-Meier estimates of (**a**) Locoregional progression free survival (LRPFS), (**b**) Distant metastasis free survival (DMFS) and (**c**) overall survival (OS) by radiation modality of patients who received 3DCRT (*n* = 80) and IMRT (*n* = 27)

Univariate and multivariate analyses in all patients {#Sec10}
----------------------------------------------------

The results of univariate analyses for LRPFS and OS are shown in Table [3](#Tab3){ref-type="table"}. Radiation modality of 3DCRT (*p* = 0.037), larger tumor (*p* = 0.047), and high pretreatment CA19--9 level (*p* = 0.010) were found to be significant unfavorable factors for OS. Younger age (*p* = 0.039), radiation modality of 3DCRT (*p* = 0.035), and high pretreatment CA19--9 level (*p* \< 0.01) were significant unfavorable factors for LRPFS.Table 3Univariate analysis of all patientsFactorsNumber of patients1-year LRPFS (%)*p*-value1-year OS (%)*p*-valueAge (years) \< 665852.60.03964.70.11 ≥664981.085.5Gender Male4571.90.8877.40.67 Female6259.572.0Tumor size \< 3 cm6465.00.1177.70.047 ≥3 cm4366.769.3Radiation modality 3DCRT8063.20.03568.20.037 IMRT2773.192.3PS 05265.20.5578.30.053 1--25566.270.5Pretreatment CA19--9 (U/ml) \< 3006476.70.002682.20.010 ≥3004350.062.8Tumor location Body/Tail5069.40.2476.00.21 Head/Neck5762.372.8*Abbreviations; LRPFS* locoregional progression free survival, *OS* overall survival

The results of multivariate analysis for OS are listed in Table [4](#Tab4){ref-type="table"}. Multivariate analyses revealed that high pretreatment CA19--9 level (*p* = 0.026) was a significant unfavorable factor and radiation modality of 3DCRT (*p* = 0.082) was a marginal unfavorable factor.Table 4Multivariate analysis of all patientsFactorsNumber of patientsOSHR (95% CI)*p*-valueRadiation modality 3DCRT80 IMRT270.64 (0.38--1.06)0.082Pretreatment CA19--9 (U/ml) \< 30064 ≥300431.62 (1.06--2.47)0.026Tumor size \< 3 cm64 ≥3 cm431.37 (0.89--2.10)0.15*Abbreviations*; *OS* overall survival, *HR* hazard ratio

Univariate and multivariate analyses in patients treated with IMRT {#Sec11}
------------------------------------------------------------------

The results of univariate analyses for LRPFS and OA are shown in Table [5](#Tab5){ref-type="table"}. Radiation dose under 45Gy (*p* \< 0.01) and high pretreatment CA19--9 level (p = 0.037) were found to be significant unfavorable factors for OS. Younger age (*p* = 0.015), radiation dose under 45Gy (p \< 0.01), and high pretreatment CA19--9 level (*p* = 0.032) were significant unfavorable factors for LRPFS. As younger age was a significant unfavorable factor, it would be important to observe younger patients closely post-CRT.Table 5Univariate analysis of IMRT patientsFactorsNumber of patients1-year LRPFS (%)*p*-value1-year OS (%)*p*-valueAge (years) \< 6612500.01583.30.21 ≥661592.9100Gender Male1768.80.6393.80.72 Female108090Tumor size \< 3 cm1972.20.3694.40.23 ≥3 cm87587.5Radiation dose \< 45 Gy933.31.23E-0788.90.000077 ≥45 Gy1894.194.1PS 015600.4186.70.47 11290.9100Pretreatment CA19--9 (U/ml) \< 3001787.50.0321000.037 ≥300105080Tumor location Body/Tail1154.50.2581.80.12 Head/Neck1686.7100*Abbreviations*; *LRPFS* locoregional progression free survival, *OS* overall survival

The results of multivariate analyses for LRPFS and OA are listed in Table [6](#Tab6){ref-type="table"}. Multivariate analyses revealed that radiation dose under 45Gy was a significant unfavorable factor for both LRPFS (p \< 0.01) and OS (*p* = 0.044). Eighteen patients in the IMRT group who were treated with ≥45 Gy had significantly better 1-year LRPFS (94.1% vs. 33.3%, p \< 0.01) and 1-year OS (94.1% vs. 88.9%, p \< 0.01) compared with IMRT patients treated with \< 45 Gy (Fig. [2](#Fig2){ref-type="fig"}). There was no significant difference of tumor sizes among IMRT patients who had been treated with under 45Gy and over 45Gy (31.4 mm vs. 27.2 mm, *p* = 0.18). The MST of patients treated with IMRT over 45Gy and under 45Gy were 28.8 months and 14.3 months, respectively.Table 6Multivariate analysis of IMRT patientsFactorsNumber of patientsLRPFSOSHR (95% CI)*p*-valueHR (95% CI)*p*-valueAge (years) \< 6612 ≥66150.23 (0.064--0.86)0.0290.86 (0.28--2.67)0.79Radiation dose \< 45 Gy9 ≥45 Gy180.043 (0.0049--0.38)4.00E-030.27 (0.077--0.96)0.044Pretreatment CA19--9 (U/ml) \< 30017 ≥300103.39 (0.85--13.54)0.0841.87 (0.63--5.55)0.26Tumor location Body/Tail11 Head/Neck160.73(0.21--2.58)0.620.61 (0.20--1.9)0.39*Abbreviations; LRPFS* locoregional progression free survival, *OS* overall survival, *HR* hazard ratioFig. 2Kaplan-Meier estimates of (**a**) Locoregional progression free survival (LRPFS) and (**b**) overall survival (OS), according to total dose ≥45 Gy or \< 45 Gy

Recurrence pattern {#Sec12}
------------------

Among the 27 patients who underwent IMRT, the first relapse occurred at locoregional in 3 patients (11.1%) and at distant organs in 16 patients (59.3%), and at both locoregional and distant organs in 1 patient (3.7%). Among the 80 patients who underwent 3DCRT, the first relapse occurred at locoregional in 24 patients (30%) and at distant organs in 42 patients (52.5%), and at both locoregional and distant organs in 4 patients (5%).

GI toxicities {#Sec13}
-------------

An overview of the acute and late GI toxicities and their grades is shown in Table [7](#Tab7){ref-type="table"}. Acute GI toxicity of grade 2 or higher occurred in 32 patients (40%) treated with 3DCRT compared with five patients (19%) treated with IMRT (*p* = 0.042). Late GI toxicity of grade 2 or higher occurred in 10 patients (12%) treated with 3DCRT compared with two patients (8%) treated with IMRT. As for late GI toxicity of grade 2 or higher, grade 3 toxicities occurred in 10 patients (12%) treated with 3DCRT and one patient (4%) treated with IMRT, respectively. GI toxicity of grade 4 or higher was not observed. The 1-year cumulative incidence rates of late GI toxicities of grade 2 or higher in the 3DCRT and IMRT groups were 11.3% (95% CI = 5.5--19.4%) and 7.6% (95% CI = 1.3--21.7%), respectively (*p* = 0.47).Table 7Acute and late gastrointestinal toxicityGr 0--1Gr 2Gr 3Gr 4Acute GI toxicity 3D-CRT48 (60%)29 (36%)3 (4%)0 (0%) IMRT22 (81%)5 (19%)0 (0%)0 (0%)Late GI toxicity 3DCRT70 (88%)0 (0%)10 (12%)0 (0%) IMRT25 (92%)1 (4%)1 (4%)0 (0%)*Abbreviations; GI* gastrointestinal

Discussion {#Sec14}
==========

The present study aimed to evaluate the effect of hypofractionated full-dose gemcitabine IMRT on GI toxicities and outcomes compared to conventionally fractionated low dose gemcitabine 3DCRT for LAPC patients.

Pancreas is surrounded by radiosensitive GI organs such as the stomach and the duodenum, and this anatomical situation makes it difficult to deliver high doses to tumor without increasing the irradiation dose to GI organs^12,13^. A previous attempt for dose-escalation when performing 3DCRT resulted in failure in LAPC; it was more toxic and less effective \[[@CR6]\]. Because IMRT can deliver high-dose radiation to the target volume while decreasing the radiation to dose-limiting adjacent critical structures, it has been suggested to be beneficial for LAPC. A systematic review showed that GI toxicities were significantly reduced with IMRT \[[@CR18]\]. Similar to the previous reports, the rates of GI toxicities were low in our study; only 4 % of IMRT patients experienced grade 3+ late GI toxicity, compared with 12% of 3DCRT patients. In addition, concerning acute hematological toxicities in the IMRT patients, grade 3 leukopenia, neutropenia and thrombocytopenia occurred in 10, 7, and 1 patients, respectively. Grade 4 neutropenia occurred in 3 patients (11%); however, all acute hematologic toxicities were able to be well managed. IMRT enabled us to use full dose gemcitabine in combination with radiotherapy of shorten fractionation without increasing GI toxicities when compared to 3DCRT.

This study revealed that patients treated with IMRT showed significantly improved LRPFS and OS compared with those treated with 3DCRT, whereas there was no significant difference in DMFS between the two groups. This suggests that better locoregional control would result in better OS. Several dose escalation studies, using IMRT technique reported hopeful results. Ben-josef et al. conducted a phase I/II trial of IMRT dose escalation in LAPC patients \[[@CR19]\]. They reported that high-dose radiation therapy, 55 Gy/25 fr. can be administered safely with concurrent full-dose gemcitabine, and the median OS after such therapy was 15 months. Recently, Krishnan et al. reported that dose escalated IMRT (BED \> 70 Gy) for the patients who had tumors \> 1-cm from the luminal organs is feasible and tolerable \[[@CR20]\]. They reported that higher dose (BED) was a strong independent predictor of improved OS in those patients. In our cohort, the patients who received over 45 Gy, using IMRT had significantly better OS than those receiving under 42 Gy of IMRT (MST 28.8 months vs. 14.3 months, *p* \< 0.01), which also suggests that dose escalation with IMRT for LAPC is a promising strategy.

As for recurrence pattern, patients who underwent IMRT had less locoregional recurrence as a first site compared with those who underwent 3DCRT (11.1% vs. 30%). Locoregional relapse is often associated with pain, gastroduodenal obstruction. Therefore, improved locoregional control would be beneficial for keeping quality of life for the patients of LAPC. On the other hand, the rate of distant metastasis as a first site is still high which is approximately 50--60%. This suggest that more efficient systemic chemotherapy is needed to treat micrometastatic spread in these patients. Low toxicity of CRT using IMRT will make it possible to receive further treatment with intensive systemic chemotherapies, and FOLFIRINOX or gemcitabine plus nab-paclitaxel regimens before or after CRT may address these issues better \[[@CR10], [@CR11]\].

As with any retrospective analysis, there are several limitations. First, the assessment of toxicities in a retrospective analysis tends to underestimate risks owing to incomplete recording of side effects and the recall bias. However, severe toxicities would have required additional medical care, which would have been clearly documented. Second, IMRT was administered as part of an institutional change in practice in 2009, rather than in a prospective controlled manner. In addition, the dose of concurrent chemotherapy and the rate of patients who received induction chemotherapy were different between the 3DCRT and IMRT patients, and respiratory management was used in IMRT patients only. However, all treatment plans were developed and conducted at one institution, limiting the bias introduced by multi-institutional plans. Third, this retrospective analysis did not directly compare the outcomes between CRT and chemotherapy for LAPC patients. Clinical studies, including the LAP07 randomized clinical trial, which could not show survival benefit of CRT over chemotherapy alone for LAPC adopted the conventional radiotherapy technique, 3DCRT \[[@CR6], [@CR8]\]. In this study, the MST of the patients treated with IMRT under 45 Gy was 14.3 months, which was approximately equal to the results of CRT or chemotherapy patients in LAP07 trial. On the other hand, the MST of the patients treated with IMRT ≥45 Gy was 28.8 months, and it is much better than the result of the patients treated with IMRT under 45 Gy. This result prompted us to verify the role of radiotherapy, especially IMRT, for LAPC patients.

In summary, our data demonstrated that LAPC patients treated with hypofractionated full-dose gemcitabine IMRT had improved OS and LRPFS without increased GI toxicities when compared to conventionally fractionated low dose gemcitabine 3DCRT, suggesting that intensified CRT, using IMRT might be beneficial for LAPC patients. To evaluate this prospectively, we are currently conducting phase II multi-institutional clinical trial of CRT, using IMRT for LAPC patients (UMIN000017521).

Conclusions {#Sec15}
===========

LAPC patients treated with hypofractionated full-dose gemcitabine IMRT had improved OS and LRPFS without increased GI toxicities when compared to those of patients treated with conventionally fractionated low dose gemcitabine 3DCRT. In IMRT patients, higher dose was an independent favorable prognostic factor for better LRPFS and OS, which suggests that dose escalation with IMRT for LAPC is a promising strategy.
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